Associated Papers
Molecular characterization of clear cell adenocarcinoma of the urinary bladder.
Jha S et al.
Histopathology, 2026
Mechanistic insights into c-Met rs368750834 mutation and a bifunctional CAR-T strategy for serous ovarian carcinoma.
Li Y et al.
Journal of Ovarian Research, 2025
Prospective study of the real impact of fusion centered genomic assays in patient management in a national collaborative group: the GETHI-XX-16 study.
Navarro P et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study.
Kozakov D et al.
Frontiers in Medicine, 2025
MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients.
Rivas S et al.
International Journal of Molecular Sciences, 2024
Comparison of Results from Two Commercially Available In-House Tissue-Based Comprehensive Genomic Profiling Solutions: Research Use Only AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit and TruSight Oncology 500 Assay.
Adams HP et al.
The Journal of Molecular Diagnostics : Jmd, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C et al.
Signal Transduction and Targeted Therapy, 2024
Recording and classifying MET receptor mutations in cancers.
Guérin C et al.
Elife, 2024
The genomic and evolutionary landscapes of anaplastic thyroid carcinoma.
Zeng PYF et al.
Cell Reports, 2024
Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India.
Mathew A et al.
Jco Global Oncology, 2024
Predicted deleterious variants in the human genome relevant to gene therapy with adeno-associated virus vectors.
Rostami MR et al.
Molecular Therapy. Methods & Clinical Development, 2023
Protocol optimization of a targeted sequencing panel for genomic profiling of bronchoalveolar lavage fluid in lung cancer.
Sather CL et al.
Cancer Medicine, 2023
Variant curation and interpretation in hereditary cancer genes: An institutional experience in Latin America.
Manotas MC et al.
Molecular Genetics & Genomic Medicine, 2023
Pharmacogenomics of in vitro response of the NCI-60 cancer cell line panel to Indian natural products.
Sankaran H et al.
Bmc Cancer, 2022
Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy.
Neron M et al.
Journal of Personalized Medicine, 2022
Circulating Cell-Free DNA-Based Comprehensive Molecular Analysis of Biliary Tract Cancers Using Next-Generation Sequencing.
Csoma SL et al.
Cancers, 2022
Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer.
Metzenmacher M et al.
Translational Oncology, 2022
MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping.
Tsai JM et al.
The Oncologist, 2021
Orthogonal MET analysis in a population-representative stage II-III colon cancer cohort: prognostic and potential therapeutic implications.
Craig SG et al.
Molecular Oncology, 2021
Novel RB1 and MET Gene Mutations in a Case with Bilateral Retinoblastoma Followed by Multiple Metastatic Osteosarcoma.
Mokánszki A et al.
Diagnostics (basel, Switzerland), 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
Identification of MicroRNA-Related Tumorigenesis Variants and Genes in the Cancer Genome Atlas (TCGA) Data.
Li C et al.
Genes, 2020
Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board.
Bernhardt EB et al.
Practical Laboratory Medicine, 2020
Somatic Mutation Profiling in Premalignant Lesions of Vulvar Squamous Cell Carcinoma.
Zięba S et al.
International Journal of Molecular Sciences, 2020
Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer.
Kim J et al.
Cancers, 2020
Juvenile papillomatosis of the breast (Swiss cheese disease) has frequent associations with PIK3CA and/or AKT1 mutations.
Guillet C et al.
Human Pathology, 2020
Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia.
Madsen MB et al.
Frontiers in Endocrinology, 2020
Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study.
Spence T et al.
Current Oncology (toronto, Ont.), 2019
Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition.
Tedaldi G et al.
Cancers, 2019
[Detection and interpretation of somatic variants in molecular pathology].
Merkelbach-Bruse S et al.
Der Pathologe, 2019
RAS Mutation in Mucinous Carcinoma of the Ovary
Panyavaranant P et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2019
Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case-control study.
Kalapanida D et al.
Oncotargets and Therapy, 2019
KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma.
Mehrad M et al.
Histopathology, 2018
Genetic Mutations in a Patient with Chronic Myeloid Leukemia Showing Blast Crisis 10 Years After Presentation.
Sklarz LM et al.
Anticancer Research, 2018
Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.
Jakobsen JN et al.
Oncotarget, 2018
Germline mutation in the TP53 gene in uveal melanoma.
Hajkova N et al.
Scientific Reports, 2018
Genetic alterations in sporadic triple negative breast cancer.
Pop LA et al.
Breast (edinburgh, Scotland), 2018
Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Yehia L et al.
Plos Genetics, 2018
Cancer genes mutation profiling in calcifying epithelial odontogenic tumour.
de Sousa SF et al.
Journal of Clinical Pathology, 2018
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.
Cortot AB et al.
Journal of the National Cancer Institute, 2017
MET in human cancer: germline and somatic mutations.
Tovar EA et al.
Annals of Translational Medicine, 2017
Variant call concordance between two laboratory-developed, solid tumor targeted genomic profiling assays using distinct workflows and sequencing instruments.
Hampel KJ et al.
Experimental and Molecular Pathology, 2017
MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering.
Montagne R et al.
Oncotarget, 2017